Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
The analysis demonstrated the strong benefits of repotrectinib in PFS, which was robust across different SAs and supported by numerically favorable results for DoR (where available) and ORR. These results, alongside the published TRIDENT-1 clinical data, further support repotrectinib as a potential new standard of care for TKI-naïve patients with <i>ROS1+</i> aNSCLC.
Authors
- Yong Yuan (ORCID: https://orcid.org/0000-0001-9720-1965)
- Ellen Korol
- Madeleine Crabtree (ORCID: https://orcid.org/0000-0001-5310-6595)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- C. Calvet
- D. Ross Camidge (ORCID: https://orcid.org/0000-0003-3430-3213)
- Greta Lozano‐Ortega
- SARAH G.C. KORPACH
- Lavanya Huria (ORCID: https://orcid.org/0000-0002-7835-0372)
- Sarah Goring (ORCID: https://orcid.org/0000-0001-8522-9354)
- Adam Lee (ORCID: https://orcid.org/0000-0001-8834-1296)
- Jürgen Wolf
- Dieter Ayers
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Yonsei University (KR)
- Cornell University (US)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (United Kingdom) (GB)
- University of Colorado Cancer Center (US)
- University Hospital Cologne (DE)
- University of Colorado Denver (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-22
- DOI
- https://doi.org/10.3390/cancers17050748
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52